Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in first human test
Disease control
Recruiting now
This early-stage trial tests a new drug called 212Pb-DOTAM-GRPR1, which delivers a tiny dose of radiation directly to cancer cells that have a specific marker (GRPR). The study will include 48 adults with advanced cancers such as prostate, breast, lung, colon, cervical, or brain …
Phase: PHASE1 • Sponsor: Orano Med Theranostics, SAS • Aim: Disease control
Last updated Jun 22, 2026 11:59 UTC